PDCD1LG2 and cutaneous melanoma: Enrichment of a CCR7+ DC signature5 was associated with improved survival not only in lung cancer, but also in cutaneous melanoma, breast, and colorectal cancer (CRC, Supplementary Fig. 1a), all of which harbour CCR7+CD274+PDCD1LG2+ DCs (Supplementary Fig. 1b–g)24–26.